64007957MMY3005 Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy – MajesTEC-7
- Phase III
- Trial Category: Hematologic
Contact(s)
Mary Beth Wilwerding, RN Admin@NEcancertrials.com
Location(s)
Available at Nebraska Cancer Specialists, Omaha and Grand Island, NE locations
Interested in More Information?
Please fill out the form below. Someone will get back to you as soon as possible.
"*" indicates required fields